Skip to main content

Table 3 Immune checkpoints in ECs

From: Immunotherapy in endometrial cancer: rationale, practice and perspectives

Immune checkpoint Expression ICBs on trials
PD-1 T-cell Pembrolizumab
nivolumab
PD-L1 Tumor cell Atezolizumab
Avelumab
Durvalumab
CTLA-4 T-cell Ipilimumab
Tremelimumab
LAG-3 T-cell
NK cell
INCAGN02385
B7-H4 tumor-associated macrophages
Tumor cell
FPA150
TIM-3 T cells, Tregs, B cells, NK cells, DCs and macrophages NA